Senti Biosciences Holdings financials
$0.3075−0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $22.0K | $0.00 | $2.6M | $4.3M |
| Gross profit | $22.0K | $0.00 | $2.6M | $4.3M |
| Gross margin | 100.0% | — | 100.0% | 100.0% |
| Operating income | -$68.8M | -$61.0M | -$92.7M | -$52.6M |
| Net income | -$61.4M | -$55.3M | -$71.1M | -$58.2M |
| Net margin | −279263.6% | — | −2774.6% | −1358.1% |
| Diluted EPS | $-2.73 | $-12.03 | $-16.01 | $-22.30 |
| EBITDA | -$60.1M | -$56.9M | -$63.2M | -$60.7M |
| Operating cash flow | -$43.4M | -$41.4M | -$52.4M | -$34.9M |
| Free cash flow | -$43.6M | -$41.4M | -$64.4M | -$76.3M |
| Diluted shares | 22.5M | 4.6M | 4.4M | 2.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $16.4M | $48.3M | $35.9M | $57.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $40.9M |
| Total debt | $0.00 | $0.00 | $97.0K | $0.00 |
| Total assets | $51.2M | $97.8M | $119.5M | $180.8M |
| Total liabilities | $45.6M | $47.1M | $52.6M | $53.5M |
| Shareholders' equity | $5.6M | $25.6M | $66.9M | $127.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology